skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Identification of endogenous surrogate ligands for human P2Y{sub 12} receptors by in silico and in vitro methods

Abstract

Endogenous ligands acting on a human P2Y{sub 12} receptor, one of the G-protein coupled receptors, were searched by in silico screening against our own database, which contains more than 500 animal metabolites. The in silico screening using the docking software AutoDock resulted in selection of cysteinylleukotrienes (CysLTs) and 5-phosphoribosyl 1-pyrophosphate (PRPP), with high free energy changes, in addition to the known P2Y{sub 12} ligands such as 2MeSADP and ADP. These candidates were subjected to an in vitro Ca{sup 2+} assay using the CHO cells stably expressing P2Y{sub 12}-G{sub 16}{alpha} fusion proteins. We found that CysLTE4 and PRPP acted on the P2Y{sub 12} receptor as agonists with the EC{sub 50} values of 1.3 and 7.8 nM, respectively. Furthermore, we analyzed the phylogenetic relationship of the P2Y, P2Y-like, and CysLT receptors based on sequence alignment followed by evolutionary analyses. The analyses showed that the P2Y{sub 12}, P2Y{sub 13}, P2Y{sub 14}, GPR87, CysLT-1, and CysLT-2 receptors formed a P2Y-related receptor subfamily with common sequence motifs in the transmembrane regions.

Authors:
 [1];  [1];  [2]
  1. Laboratory of Pharmcoinformatics, Department of Bioinformatics, Ritsumeikan University, Kusatsu, Shiga 525-8577 (Japan)
  2. Laboratory of Pharmcoinformatics, Department of Bioinformatics, Ritsumeikan University, Kusatsu, Shiga 525-8577 (Japan). E-mail: nori@is.ritsumei.ac.jp
Publication Date:
OSTI Identifier:
20713436
Resource Type:
Journal Article
Resource Relation:
Journal Name: Biochemical and Biophysical Research Communications; Journal Volume: 337; Journal Issue: 1; Other Information: DOI: 10.1016/j.bbrc.2005.09.052; PII: S0006-291X(05)02061-9; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ADP; ALIGNMENT; CALCIUM IONS; CHO CELLS; COMPUTER CODES; FREE ENERGY; GTP-ASES; IN VITRO; LIGANDS; RECEPTORS

Citation Formats

Nonaka, Yosuke, Hiramoto, Takeshi, and Fujita, Norihisa. Identification of endogenous surrogate ligands for human P2Y{sub 12} receptors by in silico and in vitro methods. United States: N. p., 2005. Web. doi:10.1016/j.bbrc.2005.09.052.
Nonaka, Yosuke, Hiramoto, Takeshi, & Fujita, Norihisa. Identification of endogenous surrogate ligands for human P2Y{sub 12} receptors by in silico and in vitro methods. United States. doi:10.1016/j.bbrc.2005.09.052.
Nonaka, Yosuke, Hiramoto, Takeshi, and Fujita, Norihisa. Fri . "Identification of endogenous surrogate ligands for human P2Y{sub 12} receptors by in silico and in vitro methods". United States. doi:10.1016/j.bbrc.2005.09.052.
@article{osti_20713436,
title = {Identification of endogenous surrogate ligands for human P2Y{sub 12} receptors by in silico and in vitro methods},
author = {Nonaka, Yosuke and Hiramoto, Takeshi and Fujita, Norihisa},
abstractNote = {Endogenous ligands acting on a human P2Y{sub 12} receptor, one of the G-protein coupled receptors, were searched by in silico screening against our own database, which contains more than 500 animal metabolites. The in silico screening using the docking software AutoDock resulted in selection of cysteinylleukotrienes (CysLTs) and 5-phosphoribosyl 1-pyrophosphate (PRPP), with high free energy changes, in addition to the known P2Y{sub 12} ligands such as 2MeSADP and ADP. These candidates were subjected to an in vitro Ca{sup 2+} assay using the CHO cells stably expressing P2Y{sub 12}-G{sub 16}{alpha} fusion proteins. We found that CysLTE4 and PRPP acted on the P2Y{sub 12} receptor as agonists with the EC{sub 50} values of 1.3 and 7.8 nM, respectively. Furthermore, we analyzed the phylogenetic relationship of the P2Y, P2Y-like, and CysLT receptors based on sequence alignment followed by evolutionary analyses. The analyses showed that the P2Y{sub 12}, P2Y{sub 13}, P2Y{sub 14}, GPR87, CysLT-1, and CysLT-2 receptors formed a P2Y-related receptor subfamily with common sequence motifs in the transmembrane regions.},
doi = {10.1016/j.bbrc.2005.09.052},
journal = {Biochemical and Biophysical Research Communications},
number = 1,
volume = 337,
place = {United States},
year = {Fri Nov 11 00:00:00 EST 2005},
month = {Fri Nov 11 00:00:00 EST 2005}
}
  • Anthropogenic compounds with the capacity to interact with the steroid-binding site of sex hormone binding globulin (SHBG) pose health risks to humans and other vertebrates including fish. Building on studies of human SHBG, we have applied in silico drug discovery methods to identify potential binders for SHBG in zebrafish (Danio rerio) as a model aquatic organism. Computational methods, including; homology modeling, molecular dynamics simulations, virtual screening, and 3D QSAR analysis, successfully identified 6 non-steroidal substances from the ZINC chemical database that bind to zebrafish SHBG (zfSHBG) with low-micromolar to nanomolar affinities, as determined by a competitive ligand-binding assay. We alsomore » screened 80,000 commercial substances listed by the European Chemicals Bureau and Environment Canada, and 6 non-steroidal hits from this in silico screen were tested experimentally for zfSHBG binding. All 6 of these compounds displaced the [{sup 3}H]5{alpha}-dihydrotestosterone used as labeled ligand in the zfSHBG screening assay when tested at a 33 {mu}M concentration, and 3 of them (hexestrol, 4-tert-octylcatechol, and dihydrobenzo(a)pyren-7(8H)-one) bind to zfSHBG in the micromolar range. The study demonstrates the feasibility of large-scale in silico screening of anthropogenic compounds that may disrupt or highjack functionally important protein:ligand interactions. Such studies could increase the awareness of hazards posed by existing commercial chemicals at relatively low cost.« less
  • Parabens are p-hydroxybenzoic acid esters that have been used extensively as preservatives in foods, cosmetics, drugs and toiletries. These intact esters are commonly detected in human breast cancer tissues and other human samples, thus arousing concern about the involvement of parabens in human breast cancer. In this study, an in vitro nuclear receptor coactivator recruiting assay was developed and used to evaluate the binding activities of parabens, salicylates and benzoates via antagonist competitive binding on the human oestrogen-related receptor γ (ERRγ), which is known as both a diagnostic biomarker and a treatment target of breast cancer. The results showed thatmore » all of the test parabens (methyl-, ethyl-, propyl-, butyl- and benzylparaben) possessed clear inverse antagonist activities on ERRγ, with a lowest observed effect level (LOEL) of 10{sup −7} M and the 50% relative effective concentrations (REC50) varying from 3.09 × 10{sup −7} to 5.88 × 10{sup −7} M, whereas the salicylates possessed much lower activities and the benzoates showed no obvious activity. In silico molecular docking analyses showed that parabens fitted well into the active site of ERRγ, with hydrogen bonds forming between the p-hydroxyl group of parabens and the Glu275/Arg316 of ERRγ. As the paraben levels reported in breast cancer tissues are commonly higher than the LOELs observed in this study, parabens may play some role via ERRγ in the carcinogenesis of human breast cancer. In addition, parabens may have significant effects on breast cancer patients who are taking tamoxifen, as ERRγ is regarded as a treatment target for tamoxifen. - Highlights: • An oestrogen-related receptor γ coactivator recruiting assay was developed. • Strong binding activities of parabens with oestrogen-related receptor γ were found. • The paraben levels reported in breast cancer tissues were higher than their LOELs. • Parabens may play some role via ERRγ in the carcinogenesis of human breast cancer. • Parabens may have significant effects in breast cancer patients taking tamoxifen.« less
  • Dopamine is able to inhibit the epinephrine-induced aggregation of human blood platelets, but the mechanism of action has not been elucidated. In this study the authors report that membranes from human blood platelets possess high affinity, saturable and stereoselective binding sites for the D/sub 1/ dopamine receptor antagonist (/sup 3/H)SCH 23390. (/sup 3/H)SCH 23390 appeared to label a single class of binding sites with a B/sub max/ of 18.6 +- 1.6 fmolmg protein and a K/sub D/ of 0.8 nM. The potencies of different dopaminergic antagonists and agonists in displacing (/sup 3/H)SCH 23390 from blood platelet membranes were similar tomore » those obtained for striatal membranes. Unlike the classically defined D/sub 1/ receptors, e.g. those in striatum, the D/sub 1/ receptor sites on platelets appeared no to be coupled to the adenylate cyclase system, hence the term D/sub 1/-like. The D/sub 1/ agonist SKF 38393 was more potent than dopamine in inhibiting platelet aggregation induced by epinephrine, and the effects of dopamine and SKF 38393 were prevented by SCH 23390. These results suggest that the inhibitory action of dopamine on the epinephrine-induced platelet aggregation is mediated through these D/sub 1/-like receptors« less